GLG News by Oncologists Specializing in Hematologic Malignancies in the U.S.

a novel compound unrelated to other available drugs that has activity in melanoma.

CMS is doing right thing. This will aviod pt fall and bedsore during hospitalzation

AGENDA is a phase 3 trial , sponsored by Genta, that will randomly assign patients with malignant melanoma to receive DTIC with or without Genasense. The trial seeks to confirm earlier findings which showed a benefit in patients with low normal LDH levels.  This group of patients does not represent...

Abraxis has entered into exculsive agreement with TRSI to evaluate therapeutic potential of up to 11 epothilones and possibly select a candidate for clinical development as anticancer agents. BMS's Ixabepilone is already in clinical trials for several soild tumors and a 4 recent phase II trials showed...

Brain metastases occur commonly in patients with NSCLC.  Current therapy is limited to the use of whole brain radiation therapy for patients with multiple brain metastases.  Standard chemotherapy agents work poorly in brain metastases from NSCLC.   Azixa acts as a vascular disrupting...

Millenium is initiating a multi-center randomized phase II trial for new patients with multiple myeloma taht will compare the effects of a combination of its agent Velcade, Revlimid ( Celgene) and Dexamethasone with or without cyclophosphamide. A better trial would be to compare Lenalinomide ( an oral...

Oncoscience's Nimotuzab is a humanized monoclonal antibody targeting EGFR which is being explored , together with radiation, in treatment of children with diffuse intrinsic pontine gliomas ( DIPG). This novel agent has good results in smaller studies for high grade gliomas and in other solid tumors...

"The FDA announced that studies of two prescription proton-pump inhibitors, omeprazole (Prilosec) and esomeprazole (Nexium), had raised concerns about their cardiovascular safety. In the same announcement, the agency said its preliminary assessment was that the problems seen in those studies were "not...

Because of the high cost of medical care in the United States, some individuals have sought care in other countries where out of pocket costs for the treatment can be markedly lower.  However, outcomes results with this apprach are largely anecdotal and the few studies that examine this approach...

Velcade is an effective and tolerable agent with excellent clinical activity in relasped or previously untreated multiple myeloma.  The current phase III EVOLVE trial will randomize patients with previously untreated myeloma to receive either velcade, lenalidomide / dexamethasone or velcade, lenalidomide...